Advanced BioScience Laboratories, Inc. Selected by PATH to Manufacture Novel Shigella Vaccine Candidate
Published: Oct 01, 2013
ROCKVILLE, Md.--(BUSINESS WIRE)--Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable production process under current Good Manufacturing Practices (cGMPs) to produce toxicology and Phase I clinical supply at its state-of-the-art facility located in Rockville, MD.
Help employers find you! Check out all the jobs and post your resume.